Preview

Эпидемиология и Вакцинопрофилактика

Расширенный поиск

Современное состояние специфической профилактики холеры

https://doi.org/10.31631/2073-3046-2018-17-1-55-61

Полный текст:

Аннотация

Угроза выноса холеры из эндемичных стран и реальность возникновения заносных эпидемических очагов остается актуальной проблемой и требует постоянного совершенствования специфической профилактики этого заболевания. Обзор посвящен анализу эффективности зарегистрированных противохолерных вакцин, а также возможным перспективам совершенствования специфической профилактики холеры. 

Об авторах

И. А. Беспалова
ФГУЗ «Ростовский-на-Дону научно-исследовательский противочумный институт» Роспотребнадзора
Россия


И. А. Иванова
ФГУЗ «Ростовский-на-Дону научно-исследовательский противочумный институт» Роспотребнадзора
Россия


Н. Д. Омельченко
ФГУЗ «Ростовский-на-Дону научно-исследовательский противочумный институт» Роспотребнадзора
Россия


А. В. Филиппенко
ФГУЗ «Ростовский-на-Дону научно-исследовательский противочумный институт» Роспотребнадзора
Россия


А. А. Труфанова
ФГУЗ «Ростовский-на-Дону научно-исследовательский противочумный институт» Роспотребнадзора
Россия


Список литературы

1. Desai S. N., Clemens J. D. An overview of cholera vaccines and their public health implications. Curr. Opin. Pediatr. 2012; 24 (1): 85–91.

2. http://www.remedium.ru/news/detail.php?ID=72454

3. Онищенко Г. Г., Кутырев В. В., Щуковская Т. Н., Смирнова Н. И., Никифоров А. К., Ерёмин С. А. и др. Специфическая профилактика холеры в современных условиях. Проблемы особо опасных инфекций. 2011; 107: 5–12.

4. http://www.who.int/mediacentre/factsheets/fs107/ru/

5. Emch M., Ali M., Park J. K., Yunus M., Sack D. A., Clemens J. D. Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity. Int. J. Epidemiol. 2006; 35 (4): 1044–1050.

6. Bishop A. L., Camilli A. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev. Vaccines. 2011; 10 (1): 79–94.

7. Lopez A. L., Gonzales M. L., Aldaba J. G., Nair G. B. Killed oral cholera vaccines: history, development and implementation challenges. Ther. Adv. Vaccines. 2014; 2 (5): 123–136.

8. Desai S. N., Pezzoli L., Alberti K. P., Martin S., Costa A., Perea W. et al. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. Hum. Vaccin. Immunother. 2016; 13 (3): 579–587.

9. http://www.un.org/russian/news/story.asp?NewsID=25212#.WVDBBJLygnQ.

10. https://www.stopcholera.org/sites/cholera/files/comparison_of_currently_manufactured_ocv.pdf .

11. Borde A., Larsson A., Holmgren J., Nygren E. Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation. Eur. J. Biopharm. 2011; 79 (3): 508–518.

12. Lopez-Gigosos R. M., Plaza E., Diez-Diaz R. M., Calvo M. J. Vaccination strategies to combat an infectious globe: oral cholera vaccines. J. Glob. Infect. Dis. 2011; 3 (1): 56–62.

13. Kabir S. Critical analysis of compositions and protective efficacies of the oral killed cholera vaccines. Clin. Vaccine Immunol. 2014; 21 (9): 1195–1205.

14. Lucas M. E., Deen J. L., von Seidlein L., Wang X. Y., Ampuero J., Puri M. et al. Effectiveness of mass oral vaccination in Beira, Mozambique. N. Engl. J. Med. 2005; 352: 757–767.

15. Lopez-Gigosos R., Garcia-Fortea P., Reina E., Plaza-Martin E. Effectiveness in prevention of travellers’ diarrhoea by an oral cholera vaccine WC/rBS. Travel Med. Infect. Dis. 2007; 5 (6): 380–384.

16. Lopez-Gigosos R., Garcia-Fortea P., Calvo M. J., Reina E., Diez-Diaz R., Plaza E. Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rBS) inactivated oral cholera vaccine in the prevention of traveller’s diarrhea. BMC Infect. Dis. 2009; 9 (1): 65.

17. Jelinek T., Kollaritsch H. Vaccination with Dukoral against travelers’ diarrhea (ETEC) and cholera. Expert. Rev. Vaccines. 2008; 7 (5): 561–567.

18. Gabutti G., Aquilina M., Cova M., Guiffrida S., Lizioli A., Protano D. et al. Prevention of fecal-orally transmitted diseases in travelers through an oral anticholeric vaccine (WC/rBS). J. Prev. Med. Hyg. 2012; 53 (4): 199–203.

19. Shin S., Desai S. N., Sah B. K., Clemens J. D. Oral vaccines against cholera. Clin. Infect. Dis. 2011; 52 (11): 1343–1349.

20. Thiem V. D., Deen J. L., von Seidlein L., Canh do G., Anh D. D., Park J. K. et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine. 2006; 24: 4297–4303.

21. World Health Organization, WHO expert committee on Biological standardization, 52nd report. 2004, Geneva, Switzerland. WHO.

22. Anh D. D., Canh D. G., Lopez A. L., Thiem V. D., Long P. T., Son N. H. et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine. 2007; 25: 1149–1155.

23. Mahalanabis D., Lopez A. L., Sur D., Deen J., Manna B., Kanungo S. et al. A randomized, placebo-controlled trial of bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE. 2008; 3 (6): 2323.

24. http://www.who.int/immunization/documents/Cholera_PP_Accomp_letter_10_Mar2010_Russian.pdf?ua=1

25. Sur D., Lopez A. L., Kanungo S., Paisley A., Manna B., Ali M. et al. Efficacy and safety of a modified killed whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374 (9702): 1694–1702.

26. Sur D., Kanungo S., Sah B., Manna B., Ali M., Paisley A. M. et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl. Trop. Dis. 2011; 5 (10): e1289.

27. Bhattacharya S. K., Sur D., Ali M., Kanungo S., You Y. A., Manna B. et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 2013; 13 (12): 1050–1056.

28. Wierzba T. F., Kar S. K., Mogasale V. V., Kerretta A. S., You Y. A., Baral P. Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. Vaccine. 2015; 33 (21): 2463–2469.

29. Kanungo S., Lopez A. L., Ali M., Manna B., Kim D. R., Mahapatra T. et al. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. PLoS One. 2014; 9 (5): e96499.

30. Jeuland M., Cook J., Poulos C., Clemens J., Whittington D.; DOMI Cholera Economics Study Group. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009; 12 (6): 899–908.

31. Saha A., Chowdhury M. I., Khanan F., Bhuiyan M. S., Chowdhury F., Khan A. I. et al. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccines Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011; 29 (46): 8285–8292.

32. Luquero F. J., Grout L., Giglenecki I., Sakoba K., Traore B., Heile M. et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N. Engl. J. Med. 2014; 370 (22): 2111–2120.

33. Desai S., Akalu Z., Teshome S., Teferi M., Yamuah L., Kim D. R. et al. A randomized, placebo-controlled trial evaluating safety and immunogenicity of the killed, bivalent, whole-cell oral cholera vaccine in Ethiopia. Am. J. Trop. Med. Hyg. 2015; 93 (3): 527–533.

34. Charles R. C., Hilaire I. J., Mayo-Smith L. M., Teng J. E., Jerome J. C., Franke M. F. et al. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. PLoS Negl. Trop. Dis. 2014; 8 (5): 2828.

35. Ivers L. C., Charles R. C., Hilaire I. J., Mayo-Smith L.M., Teng J. E., Herome J. G. Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection. J. Infect. Dis. 2015; 212 (5): 779–783.

36. Kanungo S., Paisley A., Lopez A. L., Bhattacharya M., Manna B., Kim D. R. et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: A randomized, placebo-controlled trial. Vaccine. 2009; 27 (49): 6887–6893.

37. Azman A. S., Parker L. A., Rumunu J., Tadesse F., Grandesso F., Deng L. L. et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a casecohort study. Lancet Glob. Health. 2016; 4 (11): e856–e863.

38. Baik Y. O., Choi S. K., Kim J. W., Yang J. S., Kim I. Y., Kim C. W. et al. Safety and immunogenicity assessment of an oral cholera vaccine through phase 1 clinical trial in Korea. J. Korean Med. Sci. 2014; 29 (4): 494–501.

39. Baik Y. O., Choi S. K., Olveda R. M., Espos R. A., Ligsay A. D., Montellano M. B. et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine. 2015; 33 (46): 6360–6365.

40. Chen W. H., Greenberg R. N., Pasetti M. F., Livio S., Lock M., Gurwith M. et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR prepared from new Master and Working Cell Banks. Clin. Vaccine Immunol. 2014; 21(1): 66–73.

41. Chen W. H., Cohen M. B., Kirkpatrick B. D., Brady R. C., Galloway D., Gurwith M. et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin. Infect. Dis. 2016; 62 (11):1329–1335.

42. Levine M. M., Chen W. H., Kaper J. B., Lock M., Danzig L., Gurwith M. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines. 2017; 16 (3): 197–213.

43. Онищенко Г. Г., Попова А. Ю., Кутырев В. В., Смирнова Н. И., Щербакова С. А., Москвитина Э. А. и др. Актуальные проблемы эпидемиологического надзора, лабораторной диагностики и профилактики холеры в Российской Федерации. Журн. микробиол. 2016; 1: 89–101.

44. Комиссаров А. В., Никифоров А. К., Перепелица А. И., Еремин С. А., Громова О. В., Васин Ю. Г. и др. Аппаратный метод обессоливания антигенных компонентов холерной химической вакцины. Проблемы особо опасных инфекций. 2014; 4: 61–64.

45. Еремин С. А., Щуковская Т. Н., Комиссаров А. В., Волох О. А., Громова О. В., Клюева С. Н. и др. Технология производства новой холерной химической вакцины с использованием атоксигенных штаммов Vibrio cholerae. Холера и патогенные для человека вибрионы: Материалы совещания специалистов Роспотреб- надзора по вопросам совершенствования эпидемиологического надзора за холерой. Ростов-на-Дону; 2013; 26: 232–235.

46. Ryan E. T., Calderwood S. B., Qadri F. Live attenuated oral cholera vaccines. Expert Rev. Vaccines. 2006; 5 (4): 483–494.

47. Muse M., Grandjean C., Wade T. K., Wade W. F. A one dose experimental cholera vaccine. FEMS Immunol. Med. Microbiol. 2012; 66 (1): 98–115.

48. Pastor M., Esquisabel A., Talavera A., Año G., Fernández S., Cedré B. et al. An approach to cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles. Int. J. Pharm. 2013; 448 (1): 247–58.

49. Омельченко Н. Д., Мишанькин Б. Н., Иванова И. А., Дуванова О. В. Романова Л. В., Шипко Е. С. и др. Изучение иммуногенных свойств наружных мембран холерного вибриона. Медицинская иммунология. 2015; 17 (3): 120–121.

50. Fernández S., Año G., Castaño J., Pino Y., Uribarri E., Riverón L. A. et al. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholerae. Travel. Med. Infect. Dis. 2013; 11 (2): 103–109.

51. Lebens M., Karlsson S. L., Kapgard S., Blomquist M., Ekman A., Nygren E., Holmgren J. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens. Vaccine. 2011; 29 (43): 7505–7513.

52. Ledón T., Ferrán B., Pérez C., Suzarte E., Vichi J., Marrero K. et al. TLP01, an mshA mutant of Vibrio cholerae O139 as a vaccine candidate against cholera. Microbes Infect. 2012; 14 (11): 968–978.

53. Kiaie S., Abtahi H., Mosayebi G., Alikhani M., Pakzad I. Recombinant toxin-coregulated pilus A (TcpA) as a candidate subunit cholera vaccine. Iran J. Microbiol. 2014; 6 (2): 68–73.

54. Ratanasuwan W., Kim Y. H., Sah B. K., Suwanagool S., Kim D. R., Anekthananon A. et al. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand. Vaccine. 2015; 33 (38): 4830–4836.

55. Sinha R., Koley H., Nag D., Mitra S., Mukhopadhyay A. K., Chattopadhyay B. Pentavalent outer membrane vesicles of Vibrio cholerae induce adaptive immune response and protective efficacy in both adult and passive suckling mice models. Microbes Infect. 2015; 17 (3): 215–27.

56. Jiang X. L., He Z. M., Peng Z. Q., Qi Y., Chen Q., Yu S. Y. Cholera toxin B protein in transgenic tomato fruit induces systemic immune response in mice. Transgenic Res. 2007; 16 (2): 169–175.

57. Sharma M. K., Singh N. K., Jani D., Sisodia R., Thungapathra M., Gautam J. K. et al. Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum). Plant Cell Rep. 2008; 27 (2): 307–318.

58. Kim Y. S., Kim M. Y., Kim T. G., Yang M. S. Expression and assembly of cholera toxin B subunit (CTB) in transgenic carrot (Daucus carota L.). Mol. Biotechnol. 2009; 41(1): 8–14.

59. Tokuhara D., Yuki Y., Nochi T., Kodama T., Mejima M., Kurokawa S. et al. Secretory IgA-mediated protection against Vibrio cholerae and heat-labile enterotoxinproducing enterotoxigenic Escherichia coli by rice-based vaccine. Proc. Nat. Acad. Sci. USA. 2010; 107 (19): 8794–8799.

60. Karaman S., Cunnick J., Wang K. Expression of the cholera toxin B subunit (CT-B) in maize seeds and a combined mucosal treatment against cholera and traveler’s diarrhea. Plant Cell Rep. 2012; 31 (3): 527–537.

61. Eko F.O., Okenu D. N., Singh U., He Q., Black C., Igietseme J. U. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine. 2011; 29 (21): 3802–3810.

62. Vishwakarma V., Sahoo S. S., Das S., Ray S., Hardt W. D., Suar M. Cholera toxin-B (ctxB) antigen expressing Salmonella typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection. Vaccine. 2015; 33 (15): 1880–1889.

63. Leitner D. R., Lichtenegger S., Temel P., Zingl F. G., Ratzberger D., Roier S. et al. A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbiol. 2015; 6: 823.

64. WHO/CDS/NTD/IDM/2006.2. Oral cholera vaccine use in complex emergencies situations: what next? /Report of a WHO meeting. Сairo, Egipt, 14–16 December. WHO, 2005.


Для цитирования:


Беспалова И.А., Иванова И.А., Омельченко Н.Д., Филиппенко А.В., Труфанова А.А. Современное состояние специфической профилактики холеры. Эпидемиология и Вакцинопрофилактика. 2018;17(1):55-61. https://doi.org/10.31631/2073-3046-2018-17-1-55-61

For citation:


Bespalova I.A., Ivanova I.A., Omelchenko N.D., Filippenko A.V., Trufanova A.A. Current State of Cholera Specific Prophylaxis. Epidemiology and Vaccinal Prevention. 2018;17(1):55-61. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-1-55-61

Просмотров: 419


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-3046 (Print)
ISSN 2619-0494 (Online)